Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.

dc.contributor.author	H Pakdaman
dc.contributor.author	A Fallah
dc.contributor.author	M A Sahraian
dc.contributor.author	R Pakdaman
dc.contributor.author	A Meysamie
dc.date.accessioned	2017-10-24T10:26:54Z
dc.date.available	2017-10-24T10:26:54Z
dc.date.issued	2006-Aug
dc.identifier.citation	rft.volume=37&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.spage=257&rft.issue=4&rft.epage=60&ctx_ver=Z39.88-2004&rft.jtitle=Neuropediatrics&rft.date=2006
dc.identifier.issn	0174-304X
dc.identifier.uri	http://dsp.sbmu.ac.ir/xmlui/handle/123456789/72232
dc.description.abstract	Patients with early onset multiple sclerosis may develop disability at a younger age than adults. There are several reports about safety of beta interferons in childhood and juvenile MS with different doses.
dc.source	Neuropediatrics
dc.title	Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.

Files in this item

Files	Size	Format	View
There are no files associated with this item.